Navigation Links
Installation of Next Generation Proton Therapy System Progressing Rapidly
Date:10/26/2010

LITTLETON, Mass., Oct. 26 /PRNewswire/ -- Still River Systems' groundbreaking proton therapy system is entering the final phase of installation at the Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine in St. Louis, MO, a National Cancer Institute (NCI) Comprehensive Cancer Center. The precision of proton therapy makes it an important treatment option for patients with cancer, as it spares the healthy tissue and results in far fewer short- and long-term treatment complications. This unique device houses a revolutionary proton source based on the world's first superconducting synchrocyclotron and provides a significant reduction in the size, cost and complexity of developing and operating a proton therapy center.

This next generation proton therapy system is installed in three simple phases, in a radiation therapy room comparable in surface to that of conventional radiotherapy systems. Phase 1 consists of rigging and mounting the accelerator gantry, which holds and positions the proton source with sub-millimeter accuracy.  Phase 2 includes assembling and installing the clinical environment which comprises the 6D robotic couch, the high-accuracy treatment gantry and its applicators, the 2D/3D imaging and positioning systems and the clinical software interfaces.  The third and final phase consists of the installation of the accelerator module.   "The execution of phases 1 and 2 of the first installation went very smoothly and we are targeting 2 months to complete them in future installations," explains Bill Alvord, Vice President of Operations.

The production accelerator is now undergoing clinical commissioning, and all clinical parameters have exceeded performance expectations.  "The innovative design of our proton therapy system is simple and modular thus ensuring a lean and fast production line followed by a quick and efficient system installation," states CEO Joseph Jachinowski. "With our first system produced and its installation nearing completion, we are now reaping the benefits of its unique design by finalizing a complete process that can be replicated to meet the growing proton therapy demand."

Still River Systems will be exhibiting at the 52nd Annual Meeting of the American Society for Radiation Oncology in San Diego California on October 31st through November 3rd.  

ABOUT STILL RIVER SYSTEMS

Still River Systems, Inc., based in Littleton, Massachusetts, is dedicated to providing physicians, and their patients, access to high quality, cost-effective proton therapy solutions. Still River Systems is developing the Monarch250, an affordable, precise and compact proton therapy system for cancer treatment.

The Monarch250 has not been cleared by the US Food and Drug Administration for distribution or clinical use. For more information on Still River Systems and the Monarch250 Proton Therapy System, please call 978-540-1500 or visit www.stillriversystems.com


'/>"/>
SOURCE Still River Systems
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. New TROY SecureRx Prescription Printer Marks 50th Hospital Installation Milestone
2. Heska Announces First Installation of New Blood Gas & Electrolyte Analyzer
3. Health Robotics Surpasses 100 Installations Milestone and Acquires Two I.V. Room of the Future Partner Companies
4. Low Installation Rates in Retail Pharmacies Across Europe Increase the Growth Potential of the Pharmacy Automation Systems Market, Finds Frost & Sullivan
5. Althea Technologies Announces the Installation of a High-Speed Prefilled Syringe Line
6. Abbott and AstraZeneca Announce Selection of Next-Generation Fenofibrate ABT-335 and CRESTOR(R) Fixed-Dose Combination
7. Kosans Second-Generation Hsp90 Inhibitor, Alvespimycin, Shows 42% Clinical Benefit in Phase 1 HER2-Positive Metastatic Breast Cancer Trial
8. Beaumont Patients 1st to get Next Generation of Radiation Treatment
9. Boston Scientifics Next-Generation Stent Shows Improved Clinical Outcomes in Complex Lesions
10. BiPar Announces Preclinical Data Demonstrating Anti-Tumor Activity With BSI-401, Its Second-Generation PARP Inhibitor
11. Acologix Presents Preclinical Data on Cartilage Regeneration by AC-100 at the OARSI 2007 World Congress on Osteoarthritis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... Mass. , June 24, 2016   Pulmatrix, ... pharmaceutical company developing innovative inhaled drugs, announced today that ... Russell Investments reconstituted its comprehensive set of ... "This is an important milestone for Pulmatrix," ... will increase shareholder awareness of our progress in developing ...
(Date:6/24/2016)... 2016  Arkis BioSciences, a leading innovator in ... durable cerebrospinal fluid treatments, today announced it has ... is led by Innova Memphis, followed by Angel ... investors.  Arkis, new financing will accelerate the commercialization ... release of its in-licensed Endexo® technology. ...
(Date:6/23/2016)... Research and Markets has announced the addition of ... report to their offering. ... kidney failure, it replaces the function of kidneys by removing ... thus the treatment helps to keep the patient body,s electrolytes ... Increasing number of ESRD patients & substantial healthcare expenditure ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... June 26, 2016 , ... Pixel Film Studios Released ProSlice Levels, a Media ... give their videos a whole new perspective by using the title layers in ... Studios. , ProSlice Levels contains over 30 Different presets to choose from. ...
(Date:6/26/2016)... ... June 26, 2016 , ... Many women are ... with endometriosis. These women need a treatment plan to not only alleviate symptoms ... can help for preservation of fertility and ultimately achieving a pregnancy. The specialists ...
(Date:6/25/2016)... ... ... of Bruton Memorial Library on June 21 due to a possible lice infestation, as reported ... head lice: the parasite’s ability to live away from a human host, and to infest ... in the event that lice have simply gotten out of control. , As lice are ...
(Date:6/25/2016)... ... 25, 2016 , ... As a lifelong Southern Californian, Dr. Omkar Marathe earned ... the David Geffen School of Medicine at UCLA. He trained in Internal Medicine at ... fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had the opportunity ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the benefits of moderation, ... the latter, setting the bar too high can result in disappointment, perhaps even self-loathing. ... toward their goal. , Research from PsychTests.com reveals that behind the ...
Breaking Medicine News(10 mins):